ClinicalTrials.gg
RecruitingNCT07612189Updated Sep 25, 2026

A Study of NEOK002, an EGFR and MUC1 Targeting Bispecific ADC, in Participants With Select Solid Tumors

A Phase 1 interventional study of NEOK002 and NEOK002 RDE in Locally Advanced (Unresectable) or Metastatic Solid Tumors, sponsored by NEOK Bio, Inc.. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by NEOK Bio, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a first in human (FIH), Phase 1 dose escalation and expansion study in select solid tumors. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B).

Read the detailed description

This is a FIH, Phase 1, open-label, multicenter, multiple-dose, dose escalation and expansion study. This study includes 2 parts: a Dose Escalation and Backfill portion (Part A) and a Dose Expansion portion (Part B). NEOK001 is a bispecific EGFR and MUC1 exatecan antibody-drug conjugate (ADC) that will be administered intravenously once every cycle.

02

Conditions studied

  • Locally Advanced (Unresectable) or Metastatic Solid Tumors
03

In context

Lead sponsor

NEOK Bio, Inc. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants must have locally advanced or metatstatic disease in a select tumor type, for which no standard therapy is available.
  • Participants must have at least 1 measurable target lesion based on v1.1.
  • Participants must have (ECOG) performance status of 0 or 1.
  • Participants must have adequate hematologic, hepatic, and renal function.
  • Participants should have available archived tumor tissue from their most recent .

Key Exclusion Criteria:

  • Participant's most recent systemic anti-cancer treatment was an ADC with a topoisomerase 1-inhibitor payload component.
  • Participant with known symptomatic central nervous system (CNS) or any evidence of or evidence of unstable , even if asymptomatic.
  • Participants with a known history of interstitial lung disease (ILD) requiring treatment, or for whom suspected ILD cannot be ruled out by imaging at screening.
  • Participants with clinically severe pulmonary compromise due to intercurrent pulmonary illness and/or pulmonary disorder requiring supplemental oxygen or any prior pneumonectomy.
  • Participants with a corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 msec.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
155 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    NEOK002

    Drug: NEOK002

  • Experimental
    Dose Expansion

    Recommended Dose of NEOK002 for Expansion

    Drug: NEOK002 RDE

Interventions

  • DrugNEOK002

    Escalating doses of NEOK002

  • DrugNEOK002 RDE

    Recommended NEOK002 dose(s) for Expansion

06

What researchers measure

Primary outcomes

  1. Part A: Incidence and Severity of Dose-Limiting Toxicities (DLTs)

    Incidence and severity of DLTs during the first cycle of treatment in Part A

    Time frame: 21 days

  2. Part A: Incidence and Severity of Adverse Events (AEs)

    Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients in Part A

    Time frame: Through study completion, estimated as 32 months

  3. Part B: Investigator Assessment of Objective Response Rate (ORR)

    Percentage of patients who achieve a confirmed objective response (ORR)

    Time frame: Through study completion, estimated as 32 months

  4. Part B: Duration of Response (DOR)

    The time from the first documentation of tumor response (complete or partial) until disease progression or death.

    Time frame: Through study completion, estimated as 32 months

Secondary outcomes

  1. Part B: Incidence of AEs

    Incidence of TEAEs and SAEs in participants in Part B

    Time frame: Through study completion, estimated as 32 months

  2. Maximum Concentration (Cmax) of NEOK002

    Assessment of plasma pharmacokinetics (PK) parameters of NEOK002: Cmax

    Time frame: 21 days

  3. Terminal Elimination Half Life (T1/2) of NEOK002

    Assessment of plasma PK parameters of NEOK002: T1/2

    Time frame: 21 days

07

Study locations

10 of 10 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Apr 2026 (actual). Primary completion is estimated for Feb 2029, 34 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2026
First posted
May 28, 2026
StartActual
Apr 22, 2026
Primary completionEst.
Feb 2029
CompletionEst.
Feb 2029
Last update
Sep 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Sarah Cannon Research Institute at Mary Crowley · Dallas, United StatesContact none listed→•••3000
Sep 25, 2026
Show all 1 update
  1. Sep 25, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Sarah Cannon Research Institute at Mary Crowley · Dallas, United StatesContact none listed→•••3000

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07612189
Lead sponsor
NEOK Bio, Inc.
Responsible party
Sponsor
First posted
May 28, 2026
Start date
Apr 22, 2026
Primary completion
Feb 2029 (estimated)
Completion
Feb 2029 (estimated)
Last update
Sep 25, 2026

Study contacts

Beth Lepping, RN, BSN, MS
Contact
blepping@neokbio.com
please use email

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion